219 related articles for article (PubMed ID: 26909712)
1. Desmoid Tumor Showing Intense Uptake on 68Ga PSMA-HBED-CC PET/CT.
Kanthan GL; Hsiao E; Kneebone A; Eade T; Schembri GP
Clin Nucl Med; 2016 Jun; 41(6):508-9. PubMed ID: 26909712
[TBL] [Abstract][Full Text] [Related]
2. Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT.
Kanthan GL; Izard MA; Emmett L; Hsiao E; Schembri GP
Clin Nucl Med; 2016 Sep; 41(9):703-4. PubMed ID: 27405039
[TBL] [Abstract][Full Text] [Related]
3. Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.
Kanthan GL; Coyle L; Kneebone A; Schembri GP; Hsiao E
Clin Nucl Med; 2016 Jun; 41(6):500-1. PubMed ID: 26914565
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.
Kanthan GL; Drummond J; Schembri GP; Izard MA; Hsiao E
Clin Nucl Med; 2016 Apr; 41(4):331-2. PubMed ID: 26646999
[TBL] [Abstract][Full Text] [Related]
6. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA-HBED-CC-Avid Synchronous Urinary Bladder Paraganglioma in a Patient With Metastatic Prostate Carcinoma.
Parihar AS; Vadi SK; Mittal BR; Kumar R; Bal A; Singh SK
Clin Nucl Med; 2018 Sep; 43(9):e329-e330. PubMed ID: 29916916
[TBL] [Abstract][Full Text] [Related]
10. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
[TBL] [Abstract][Full Text] [Related]
11. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-PSMA Uptake in Angiolipoma.
Dekker I; van der Leest M; van Rijk MC; Gerritsen WR; Arens AIJ
Clin Nucl Med; 2018 Oct; 43(10):757-758. PubMed ID: 30153142
[TBL] [Abstract][Full Text] [Related]
13. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
14. Frusemide aids diagnostic interpretation of
Fennessy N; Lee J; Shin J; Ho B; Ali SA; Paschkewitz R; Emmett L
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852
[TBL] [Abstract][Full Text] [Related]
15.
Rischpler C; Beck TI; Okamoto S; Schlitter AM; Knorr K; Schwaiger M; Gschwend J; Maurer T; Meyer PT; Eiber M
J Nucl Med; 2018 Sep; 59(9):1406-1411. PubMed ID: 29371407
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Test-Retest Measurement of
Pollard JH; Raman C; Zakharia Y; Tracy CR; Nepple KG; Ginader T; Breheny P; Sunderland JJ
J Nucl Med; 2020 Aug; 61(8):1145-1152. PubMed ID: 31806776
[TBL] [Abstract][Full Text] [Related]
17. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
18. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.
Chakraborty PS; Tripathi M; Agarwal KK; Kumar R; Vijay MK; Bal C
Clin Nucl Med; 2015 Feb; 40(2):e163-6. PubMed ID: 25275415
[TBL] [Abstract][Full Text] [Related]
19. Lumbar Osteophyte Avid on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Jochumsen MR; Madsen MA; Gammelgaard L; Bouchelouche K
Clin Nucl Med; 2018 Jun; 43(6):456-457. PubMed ID: 29538033
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal Stromal Tumor Showing Intense Tracer Uptake on PSMA PET/CT.
Noto B; Weckesser M; Buerke B; Pixberg M; Avramovic N
Clin Nucl Med; 2017 Mar; 42(3):200-202. PubMed ID: 28072616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
